Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

febrero 11, 2022

Dominguez-Moreno, Rogelioa; Do, Thien Phua; Ashina, Messouda,b

Current Opinion in Endocrinology & Diabetes and Obesity: January 21, 2022 – Volume – Issue –

doi: 10.1097/MED.0000000000000717


Purpose of review 

To review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine.

Recent findings 

Randomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium.


Here, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.

Visto en: